Shattuck Labs (NASDAQ:STTK) Given Sell (D-) Rating at Weiss Ratings

Shattuck Labs (NASDAQ:STTK)‘s stock had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

STTK has been the topic of a number of other research reports. Leerink Partners reduced their price objective on Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Thursday, August 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research note on Thursday, August 14th. Wall Street Zen raised Shattuck Labs from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Finally, Wedbush assumed coverage on Shattuck Labs in a research report on Monday, September 8th. They set an “outperform” rating and a $4.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.00.

Shattuck Labs Price Performance

NASDAQ:STTK opened at $2.39 on Wednesday. Shattuck Labs has a 1 year low of $0.69 and a 1 year high of $2.70. The stock’s 50 day simple moving average is $1.54 and its two-hundred day simple moving average is $1.15. The company has a market cap of $114.48 million, a price-to-earnings ratio of -1.98 and a beta of 1.89.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. As a group, analysts anticipate that Shattuck Labs will post -1.48 EPS for the current year.

Insider Activity at Shattuck Labs

In other Shattuck Labs news, Director Mona Ashiya acquired 6,306,127 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average price of $0.87 per share, for a total transaction of $5,486,330.49. Following the acquisition, the director directly owned 5,255,106 shares in the company, valued at $4,571,942.22. The trade was a -600.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Orbimed Advisors Llc acquired 6,306,127 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were acquired at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the acquisition, the director owned 5,255,106 shares in the company, valued at $4,571,942.22. This trade represents a -600.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Shattuck Labs

Large investors have recently bought and sold shares of the business. AQR Capital Management LLC boosted its holdings in Shattuck Labs by 265.4% during the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after acquiring an additional 31,355 shares during the period. Qube Research & Technologies Ltd purchased a new position in Shattuck Labs during the 2nd quarter valued at $44,000. Nuveen LLC purchased a new position in Shattuck Labs during the 1st quarter valued at $50,000. Bridgeway Capital Management LLC boosted its holdings in Shattuck Labs by 147.5% during the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock valued at $73,000 after acquiring an additional 55,000 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Shattuck Labs during the 1st quarter valued at $81,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.